Research Institute of Influenza in St. Petersburg is Going to Develop 6th Russian COVID-19
Health News, Delhi- Magazine: Research Institute of Influenza in St. Petersburg has completed preclinical trials of a new vaccine against coronavirus.
The Smorodintsev Influenza Research Institute in St. Petersburg expects to begin clinical trials of its COVID-19 vaccine by the end of the year, said the director of the institution Dmitry Lioznov.
According to him, preclinical tests have already ended and now the institute is submitting documents for approval of the next stage. Lioznov noted that their drug will protect against both coronavirus infection and influenza A. “Such developments are underway. And I hope that if everything goes well, then before the New Year we will begin a clinical trial,” he concluded.There are now five COVID-19 vaccines registered in Russia . The first of these, Sputnik V , developed by the Gamaleya National Research Center for Epidemiology and Microbiology with the support of the RDIF , is widely used for mass vaccination and has been approved in 70 countries. Russians also have access to “EpiVacCorona” , created by the Novosibirsk center “Vector”, and “KoviVak” from the Chumakov Center of the Russian Academy of Sciences.
For revaccination, Sputnik Light is recommended – a light version of Sputnik V, which assumes a single injection of the drug. Last week, the Ministry of Health registered EpiVacCoron-N – this vaccine has the same active ingredient as in EpiVacCoron, but they are synthesized in different ways.
